{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:05Z","timestamp":1777630505930,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00012"],"award-info":[{"award-number":["75N93021C00012"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126441","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T14:58:49Z","timestamp":1729090729000},"page":"126441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults"],"prefix":"10.1016","volume":"42","author":[{"given":"Varun K.","family":"Phadke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Gromer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina A.","family":"Rebolledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Graciaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanthia","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maranda","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigisty","family":"Girmay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele P.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Capone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sommella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Vitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Retallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Seetahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Koller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Tsong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Neill-Gubitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine G.","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126441_bb0005","series-title":"WHO expert consultation on rabies: Third report [internet]","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.vaccine.2024.126441_bb0010","article-title":"Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57(RR-3):1\u201328","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"18","key":"10.1016\/j.vaccine.2024.126441_bb0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","article-title":"Use of a modified Preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.126441_bb0025","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4(115):115ra2","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126441_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","article-title":"Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials","volume":"12","author":"Capone","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126441_bb0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/fvl-2016-0070","article-title":"Simian adenoviruses as vaccine vectors","volume":"11","author":"Morris","year":"2016","journal-title":"Future Virol"},{"issue":"25","key":"10.1016\/j.vaccine.2024.126441_bb0040","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"10267","key":"10.1016\/j.vaccine.2024.126441_bb0045","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126441_bb0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2024.126441_bb0055","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126441_bb0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126441_bb0070","doi-asserted-by":"crossref","unstructured":"Ewer KJ, Sierra-Davidson K, Salman AM, et al. Progress with viral vectored malaria vaccines: A multi-stage approach involving \u201cunnatural immunity.\u201d Vaccine 2015; 33(52):7444\u20137451.","DOI":"10.1016\/j.vaccine.2015.09.094"},{"key":"10.1016\/j.vaccine.2024.126441_bb0075","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4(115):115ra1","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.126441_bb0080","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7(300):300ra126","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126441_bb0085","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-5247(22)00126-4","article-title":"Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-Centre, phase 1 clinical trial","volume":"3","author":"Jenkin","year":"2022","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126441_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008459","article-title":"A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C","volume":"14","author":"Napolitano","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126441_bb0095","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126441_bb0100","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/infdis\/jiac481","article-title":"Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12-23 months of age","volume":"227","author":"D\u00edez-Domingo","year":"2023","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiad271","article-title":"Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1\/2 randomized trial","volume":"229","author":"S\u00e1ez-Llorens","year":"2024","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126441_bb0110","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"22","key":"10.1016\/j.vaccine.2024.126441_bb0115","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2024.126441_bb0120","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2024.126441_bb0125","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1128\/JVI.01749-06","article-title":"Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity","volume":"80","author":"Thorner","year":"2006","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126441_bb0130","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126441_bb0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciy983","article-title":"Comparative immunogenicity and safety trial of 2 different schedules of single-visit intradermal rabies Postexposure vaccination","volume":"69","author":"Soentjens","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"48","key":"10.1016\/j.vaccine.2024.126441_bb0140","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1016\/j.vaccine.2016.09.058","article-title":"Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans","volume":"34","author":"Mansfield","year":"2016","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2024.126441_bb0145","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.vaccine.2006.02.027","article-title":"Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity","volume":"24","author":"Suwansrinon","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126441_bb0150","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiab034","article-title":"Long-term memory response after a single intramuscular rabies booster vaccination 10-24 years after primary immunization","volume":"226","author":"De Pijper","year":"2022","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126441_bb0155","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy420","article-title":"Rabies antibody response after booster immunization: a systematic review and Meta-analysis","volume":"67","author":"Langedijk","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126441_bb0160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1473-3099(23)00452-8","article-title":"Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial","volume":"24","author":"Overduin","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126441_bb0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450\u2013451","author":"Xiang","year":"2014","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126441_bb0170","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1080\/21645515.2021.1893575","article-title":"Quantitative characterization of the T cell receptor repertoires of human immunized by rabies virus vaccine","volume":"17","author":"Zhao","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126441_bb0175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/cid\/ciad304","article-title":"Side-by-side comparative study of the immunogenicity of the intramuscular and intradermal rabies post-exposure prophylaxis regimens in a cohort of suspected rabies virus exposed individuals","volume":"77","author":"Auerswald","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126441_bb0180","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126441_bb0185","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000468","article-title":"T cell immune memory after covid-19 and vaccination","volume":"2","author":"Wang","year":"2023","journal-title":"BMJ Med"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126441_bb0195","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0200","doi-asserted-by":"crossref","first-page":"2175558","DOI":"10.1080\/21645515.2023.2175558","article-title":"Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster","volume":"19","author":"Ulaszewska","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0205","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/s41598-018-35755-z","article-title":"Efficacy of a T cell-biased adenovirus vector as a Zika virus vaccine","volume":"8","author":"Bullard","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126441_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41541-023-00762-3","article-title":"Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection","volume":"8","author":"Lu","year":"2023","journal-title":"NPJ Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2401123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2401123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:43:36Z","timestamp":1741887816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2401123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X2401123X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126441","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126441"}}